Table 8.

Univariate and multivariate analysis of cardiovascular events and deaths versus glucose intolerance/obesity

Variables	General Population (n = 2,545)				Men (n = 1,251)				Women (n = 1,294)
	Univariate Analysis	Multivariate Analysis			Univariate Analysis	Multivariate Analysis			Univariate Analysis	Multivariate Analysis
	P	P	HR	95% CI	P	P	HR	95% CI	P	P	HR	95% CI
Age, yr	<0.0001	<0.0001	1.08	1.0–1.1	<0.0001	<0.0001	1.08	1.0–1.1	<0.0001	<0.0001	1.09	1.0–1.1
hsCRP elevateda, mg/L	<0.0001	0.002	1.90	1.3–2.9	<0.0001	<0.0001	3.06	1.8–5.3	ns	ns	ns	ns
HDL, mg/dL	<0.0001	<0.0001	0.97	0.93–0.98	0.003	0.041	0.97	0.9–1.0	ns	ns	ns	ns
LDL, mg/dL	0.013	0.251	1.00	0.99–1.00	ns	ns	ns	ns	0.001	0.681	1.00	1.0–1.1
Diabetes mellitus	<0.0001	<0.0001	3.51	2.4–5.1	<0.0001	0.025	2.02	1.1–3.2	ns	ns	ns	ns
Glucose intolerance (100–125 mg/dL)	<0.0001	<0.0001	2.13	1.5–3.1	<0.0001	0.001	2.11	1.4–3.3	<0.0001	0.052	1.84	1.0–3.4
BMI, kg/m2	<0.0001	<0.0001	2.78	1.9–4.1	<0.0001	0.7	0.98	0.9–1.1	ns	ns	ns	ns
Triglycerides, mg/dL	<0.0001	0.375	1.00	0.99–1.00	0.001	0.224	1.00	0.99–1.0	0.003	0.518	1.00	1.0–1.1
Hypertension	<0.0001	0.083	1.52	0.95–2.44	<0.0001	0.130	1.59	0.9–2.9	<0.0001	0.311	1.48	0.7–3.1
Metabolic syndrome	<0.0001	0.250	0.75	0.46–1.22	<0.0001	0.114	0.57	0.3–1.1	<0.0001	0.672	0.85	0.4–1.8
HOMA index	<0.0001	0.095	1.06	0.99–1.14	<0.0001	0.068	1.07	1.0–1.2	<0.0001	0.702	1.02	0.9–1.2
MAFLD	<0.0001	0.758	1.06	0.71–1.59	0.006	0.735	1.09	0.7–1.8	<0.0001	0.442	1.27	0.7–2.4
VAT elevatedb	0.0018	0.367	0.80	0.49–1.30	0.005	0.517	1.25	0.6–2.5	ns	ns	ns	ns

BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; MAFLD, metabolic (dysfunction)-associated fatty liver disease; ns, not significant; VAT, visceral adipose tissue.

^aValues above the upper reference limit for CRP (>5 mg/L).

^bValues in the three upper quartiles of the VAT distribution (Q2, Q3, Q4) >16 mm.